<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03169244</url>
  </required_header>
  <id_info>
    <org_study_id>16-1064</org_study_id>
    <secondary_id>1R21AA025186-01</secondary_id>
    <nct_id>NCT03169244</nct_id>
  </id_info>
  <brief_title>Buproprion for Binge Drinking</brief_title>
  <official_title>Efficacy and Safety of the Melanocortin Activator Bupropion in Treating Binge Drinking</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present proposal is an innovative and translational clinical trial derived from exciting&#xD;
      preclinical findings to test the hypothesis that treatment with the melanocortin activator&#xD;
      bupropion can reduce binge drinking in humans. Furthermore, pilot data on moderating effects&#xD;
      of coexisting nicotine use on the efficacy of bupropion for binge drinking population will be&#xD;
      obtained. Evidence for an efficacy signal with good tolerability with this FDA approved&#xD;
      medication would form the foundation to conduct a well-powered Phase II b trial. The&#xD;
      development of an effective pharmacotherapy for binge drinking would be a significant&#xD;
      clinical advance.&#xD;
&#xD;
      .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The design is a 1:1 random assignment to placebo or bupropion XL (extended release)&#xD;
      (300mg/d). The study biostatistician, will prepare the randomization schedule and include&#xD;
      blocking by gender and nicotine dependence. Randomization will be based on a stratified block&#xD;
      design, with gender and nicotine dependence as the stratification variables with&#xD;
      medication/placebo randomly assigned in blocks of four.&#xD;
&#xD;
      Bupropion XL will be initiated at 150 mg/d on Days 1-4 and increased to 300 mg/d for Days&#xD;
      5-84. The University of North Carolina (UNC) Hospital's Investigational Drug Services (IDS)&#xD;
      will prepare opaque capsules containing bupropion XL 150/300 mg and matching placebo.&#xD;
      Capsules will be inserted into blister packs with each pack containing 1 week of medication.&#xD;
      The IDS will receive the randomization schedule from our statistician and prepare the blister&#xD;
      packs according to the blocked schedule with blocking for gender/nicotine dependence.&#xD;
&#xD;
      Recruitment, Telephone Screen, and Full Eligibility Screening: Subjects will initially be&#xD;
      prescreened by phone and then at full screening read and sign the informed consent. A&#xD;
      breathalyzer test will be administered (must be 0.00 gms/dl to give informed consent),&#xD;
      height, weight and BMI recorded and a medical history and examination completed.&#xD;
      Over-the-counter and prescription medication use will be recorded and nicotine use&#xD;
      documented. Complete Blood Count (CBC) with differential; serum bilirubin, Aspartate&#xD;
      Aminotransferase (AST), Alanine Aminotransferase (ALT), Gamma-Glutamyl Transferase (GGT,)&#xD;
      sodium, potassium, chloride, blood urea nitrogen, creatinine, glucose; and urinalysis and&#xD;
      urine toxicology completed. Women will be given a urine pregnancy test (Ub-HCG) at screening&#xD;
      and at weeks 4, 8, and 12. Trained interviewers will conduct the psychiatric screening&#xD;
      interview using the M.I.N.I. . The Structured Clinical Interview (SCID) Substance Use&#xD;
      Disorders Module to establish Diagnostic and Statistical Manual (DSM-V) criteria for alcohol&#xD;
      use disorders will be administered by one of the study doctors. The study coordinator will&#xD;
      conduct the pretreatment 90-day Timeline Followback (TLFB) interview to identify amount of&#xD;
      alcohol consumed and timeframe of consumption. A binge drinking episode requires a minimum of&#xD;
      5/4 (men/women) standard drinks consumed over about a two hour period, i.e. consuming a&#xD;
      bottle of wine over five hours would not be coded as a binge drinking day. The Penn Alcohol&#xD;
      Craving Scale (PACS) and the University of Rhode Island Change Assessment (URICA) will be&#xD;
      completed and treatment goal-abstinence vs. reduction- recorded.&#xD;
&#xD;
      Initial Treatment Visit (within 21 days screening): Eligible individuals will not be required&#xD;
      to abstain from drinking alcohol prior to randomization. The study coordinator will&#xD;
      administer a breathalyzer test (BAC must be â‰¤0.04 gms/d) and complete assessments as outlined&#xD;
      in Table 1, Protection of Human Subjects. A salivary cotinine sample will be taken A 1-week&#xD;
      blister pack of bupropion-XL or placebo with written instructions will be dispensed from the&#xD;
      Investigational Drug Services according to the randomization block along with a 1-week&#xD;
      back-up blister pack in case of delayed appointments or lost doses. Bupropion-XL will be&#xD;
      titrated with 150 mg given daily for 4 days followed by 300 mg/d. Participants will be given&#xD;
      a calendar style diary to track pill taking, drinking quantity/timing, intoxication and any&#xD;
      side effects. Finally, participants will receive Medical Management from a trained clinician.&#xD;
&#xD;
      Subsequent Treatment Visits: TLFB and PACS are gathered each visit, cotinine samples at weeks&#xD;
      4, 8 and 12 and URICA at week 8. Medical monitoring will be conducted by study physicians and&#xD;
      will consist of review of vital signs, concomitant medication use, and general inquiries into&#xD;
      side effects. The physician may recommend that medication be held for a period of time to&#xD;
      deal with an adverse event, e.g. nausea. One month and three months following the last visit&#xD;
      subjects will be contacted by phone to update drinking (TLFB), adverse effects and&#xD;
      medications.&#xD;
&#xD;
      Medical Management Intervention: The psychosocial support for the study will be Medical&#xD;
      Management (MM). MM sessions average 10-15 minutes and focus on three main areas: (1)&#xD;
      feedback on consequences of drinking; (2) encouraging compliance with medication/addressing&#xD;
      compliance problems and (3) encouraging progress towards drinking goal- reduction or&#xD;
      abstinence are acceptable. 10% of sessions will be audiotaped and reviewed to enhance&#xD;
      fidelity.&#xD;
&#xD;
      Medication Compliance Monitoring: Participants will record their pill taking in&#xD;
      calendar-style diaries that will be provided and collected at each visit. Pills will be&#xD;
      distributed in blister packs that will be returned to the study coordinator to reconcile any&#xD;
      unused medication from the returned blister packs with participants' diary records.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 4, 2017</start_date>
  <completion_date type="Actual">September 17, 2019</completion_date>
  <primary_completion_date type="Actual">August 19, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The design is a 1:1 random assignment to placebo or bupropion XL (300mg/d).</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Proportion of Binge Drinking Days</measure>
    <time_frame>Randomization (Week 0) to Week 12</time_frame>
    <description>Frequency is assessed as number of binge episodes/time in trial controlling for missing data.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the Intensity of Binge Drinking</measure>
    <time_frame>Randomization (Week 0) to Week 12</time_frame>
    <description>Intensity is defined as the number of drinks per binge day scaled by the minimum threshold of a binge episode per gender (4 drinks/day for females; 5 drinks/day for males). Accordingly, if a female consumed 4 drinks in a binge drinking day, the intensity would be 1.0 and a female who consumed 6 drinks in a binge drinking day would have an intensity of 1.5.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in GGT</measure>
    <time_frame>Randomization (Week 0) to Week 12</time_frame>
    <description>Change in serum Gamma-glutamyltransferase (GGT) levels</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Alcohol Abuse</condition>
  <arm_group>
    <arm_group_label>Bupropion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bupropion extended release</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo oral tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupropion</intervention_name>
    <description>Bupropion XL will be initiated at 150 mg/d on Days 1-4 and increased to 300 mg/d for Days 5-84.</description>
    <arm_group_label>Bupropion</arm_group_label>
    <other_name>Wellbutrin Extended Release</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Placebo will be initiated on Day 1 and continue throughout the course of the study.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men and women between the ages of 21 and 44 years.&#xD;
&#xD;
          2. A minimum of 5/3 (men/women) or more binge drinking episodes per month over the past&#xD;
             three months. A binge drinking episode is defined as the consumption of 5/4&#xD;
             (men/women) standard drinks (~12 gms ethanol) in about a two hour period. Subjects may&#xD;
             meet DSM-V criteria for mild or moderate alcohol use disorder.&#xD;
&#xD;
          3. Ability to understand and sign written informed consent.&#xD;
&#xD;
          4. Must have a 0.0 gms/dl breathalyzer reading on the day of screening and 0.0 gms/dl on&#xD;
             the day of randomization.&#xD;
&#xD;
          5. BMI â‰¥18.5 (normal weight or above)&#xD;
&#xD;
          6. Express a desire to achieve abstinence or to reduce alcohol consumption&#xD;
&#xD;
          7. Must have a stable residence and be able to identify an individual who could contact&#xD;
             participant if needed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of physical dependence on alcohol as assessed by clear tolerance to alcohol&#xD;
             or alcohol withdrawal symptoms based on SCID interview or a Severe Alcohol Use&#xD;
             Disorder (&gt;5 SCID DSM-V symptoms).&#xD;
&#xD;
          2. Bupropion is contraindicated in individuals with a history of bulimia or a seizure&#xD;
             disorder&#xD;
&#xD;
          3. Clinically significant medical disease that might interfere with the evaluation of the&#xD;
             study medication or present a safety concern (e.g., renal insufficiency, cirrhosis,&#xD;
             unstable hypertension, diabetes mellitus, seizure disorder). Clinically significant&#xD;
             psychiatric illness including any psychotic disorder, bipolar disorder,&#xD;
             anorexia/bulimia, severe depression, or suicidal ideation.&#xD;
&#xD;
          4. Other substance abuse or dependence disorder other than nicotine or cannabis abuse.&#xD;
&#xD;
          5. Concurrent use of anticonvulsants. Concurrent use of any psychotropic medication&#xD;
             including antidepressants, mood stabilizers, antipsychotics, anxiolytics, stimulants,&#xD;
             or hypnotics with the exception of stable doses of antidepressants for one month.&#xD;
             Bupropion is commonly added to antidepressants for augmentation so the use of another&#xD;
             antidepressant does not represent a safety concern. .Prior history of adverse reaction&#xD;
             to bupropion.&#xD;
&#xD;
          6. AST or ALT &gt; 3.5 times Upper Limit of Normal (ULN) or bilirubin &gt; 1.5 X ULN.&#xD;
&#xD;
          7. Positive urine toxicology screen with the exception of cannabis. Individuals with&#xD;
             positive cannabis screens will be excluded only if they have a history of cannabis&#xD;
             dependence.&#xD;
&#xD;
          8. Pregnant women and women of childbearing potential who do not practice a medically&#xD;
             acceptable form of birth control (oral or depot contraceptive, or barrier methods such&#xD;
             as diaphragm or condom with spermicidal).&#xD;
&#xD;
          9. Women who are breastfeeding.&#xD;
&#xD;
         10. Individuals requiring inpatient treatment or more intense outpatient treatment for&#xD;
             their alcohol problems.&#xD;
&#xD;
         11. Participation in any clinical trial within the past 60 days that would have safety&#xD;
             concerns for the trial.&#xD;
&#xD;
         12. Court-mandated participation in alcohol treatment or pending incarceration.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James C Garbutt</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNC Chapel Hill</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>May 11, 2017</study_first_submitted>
  <study_first_submitted_qc>May 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2017</study_first_posted>
  <results_first_submitted>August 6, 2020</results_first_submitted>
  <results_first_submitted_qc>August 24, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 26, 2020</results_first_posted>
  <last_update_submitted>August 24, 2020</last_update_submitted>
  <last_update_submitted_qc>August 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of North Carolina, Chapel Hill</investigator_affiliation>
    <investigator_full_name>James Garbutt, MD</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Binge Drinking</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 26, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT03169244/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bupropion XL</title>
          <description>Bupropion XL (extended release) will be initiated at 150 mg/d on Days 1-4 and increased to 300 mg/d for Days 5-84.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo will be initiated on Day 1 and continue throughout the course of the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Randomly Assigned</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Intervention</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bupropion XL</title>
          <description>Bupropion XL (extended release) will be initiated at 150 mg/d on Days 1-4 and increased to 300 mg/d for Days 5-84.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo will be initiated on Day 1 and continue throughout the course of the study.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="18"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.2" spread="7.26"/>
                    <measurement group_id="B2" value="24.4" spread="3.57"/>
                    <measurement group_id="B3" value="25.4" spread="5.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="18"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="18"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="18"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="18"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Marital Status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Married</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="18"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Divorced/Separated</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="18"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Single, Never Married</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="18"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Years Education</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="18"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.7" spread="2.27"/>
                    <measurement group_id="B2" value="16.2" spread="1.48"/>
                    <measurement group_id="B3" value="16.0" spread="1.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking History</title>
          <population>Data missing for two participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Never Smoked</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="18"/>
                    <count group_id="B3" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Less than or equal to 1/2 Pack/Day</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="18"/>
                    <count group_id="B3" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greater than or equal to 1 Pack/Day</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="18"/>
                    <count group_id="B3" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alcohol Use</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="18"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.6" spread="6.02"/>
                    <measurement group_id="B2" value="7.2" spread="3.78"/>
                    <measurement group_id="B3" value="8.0" spread="5.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean Proportion Binge Drinking 90 Days Before Screening</title>
          <description>A Binge Drinking Day is defined as consumption of 5 (Male) or 4 (Female) standard alcohol drinks within a 2-hour period.</description>
          <units>Proportion of Binge Drinking Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="18"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.27" spread="0.13"/>
                    <measurement group_id="B2" value="0.21" spread="0.09"/>
                    <measurement group_id="B3" value="0.24" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Intensity per Binge Drinking Episode</title>
          <description>Intensity is defined as the number of drinks per binge day scaled by the minimum threshold of a binge episode per gender (4 drinks/day for females; 5 drinks/day for males). Accordingly, if a female consumed 4 drinks in a binge drinking day, the intensity would be 1.0 and a female who consumed 6 drinks in a binge drinking day would have an intensity of 1.5.</description>
          <units>unitless</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="18"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.64" spread="0.35"/>
                    <measurement group_id="B2" value="1.70" spread="0.53"/>
                    <measurement group_id="B3" value="1.67" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Drinks per Binge Drinking Episode</title>
          <units>Drinks per Binge Episode</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="18"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.02" spread="1.31"/>
                    <measurement group_id="B2" value="7.24" spread="2.23"/>
                    <measurement group_id="B3" value="7.12" spread="1.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gamma-glutamyltransferase (GGT)</title>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="18"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.6" spread="23.8"/>
                    <measurement group_id="B2" value="25.0" spread="17.2"/>
                    <measurement group_id="B3" value="27.6" spread="21.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Proportion of Binge Drinking Days</title>
        <description>Frequency is assessed as number of binge episodes/time in trial controlling for missing data.</description>
        <time_frame>Randomization (Week 0) to Week 12</time_frame>
        <population>Data unavailable for one placebo participant who did not provide any Timeline Follow Back data (TLFB).</population>
        <group_list>
          <group group_id="O1">
            <title>Bupropion XL</title>
            <description>Bupropion XL (extended release) will be initiated at 150 mg/d on Days 1-4 and increased to 300 mg/d for Days 5-84.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo will be initiated on Day 1 and continue throughout the course of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Proportion of Binge Drinking Days</title>
          <description>Frequency is assessed as number of binge episodes/time in trial controlling for missing data.</description>
          <population>Data unavailable for one placebo participant who did not provide any Timeline Follow Back data (TLFB).</population>
          <units>Binge Drinking Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="0.12"/>
                    <measurement group_id="O2" value="-0.11" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in the Intensity of Binge Drinking</title>
        <description>Intensity is defined as the number of drinks per binge day scaled by the minimum threshold of a binge episode per gender (4 drinks/day for females; 5 drinks/day for males). Accordingly, if a female consumed 4 drinks in a binge drinking day, the intensity would be 1.0 and a female who consumed 6 drinks in a binge drinking day would have an intensity of 1.5.</description>
        <time_frame>Randomization (Week 0) to Week 12</time_frame>
        <population>Data unavailable for one placebo participant who did not provide any Timeline Follow Back data (TLFB).</population>
        <group_list>
          <group group_id="O1">
            <title>Bupropion XL</title>
            <description>Bupropion XL (extended release) will be initiated at 150 mg/d on Days 1-4 and increased to 300 mg/d for Days 5-84.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo will be initiated on Day 1 and continue throughout the course of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Intensity of Binge Drinking</title>
          <description>Intensity is defined as the number of drinks per binge day scaled by the minimum threshold of a binge episode per gender (4 drinks/day for females; 5 drinks/day for males). Accordingly, if a female consumed 4 drinks in a binge drinking day, the intensity would be 1.0 and a female who consumed 6 drinks in a binge drinking day would have an intensity of 1.5.</description>
          <population>Data unavailable for one placebo participant who did not provide any Timeline Follow Back data (TLFB).</population>
          <units>unitless</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.48"/>
                    <measurement group_id="O2" value="-0.09" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in GGT</title>
        <description>Change in serum Gamma-glutamyltransferase (GGT) levels</description>
        <time_frame>Randomization (Week 0) to Week 12</time_frame>
        <population>Data unavailable for one placebo participant who did not provide GGT data.</population>
        <group_list>
          <group group_id="O1">
            <title>Bupropion XL</title>
            <description>Bupropion XL (extended release) will be initiated at 150 mg/d on Days 1-4 and increased to 300 mg/d for Days 5-84.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo will be initiated on Day 1 and continue throughout the course of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in GGT</title>
          <description>Change in serum Gamma-glutamyltransferase (GGT) levels</description>
          <population>Data unavailable for one placebo participant who did not provide GGT data.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8" spread="67.3"/>
                    <measurement group_id="O2" value="-1.8" spread="9.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From randomization through study follow-up, a total of approximately 16 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Bupropion XL</title>
          <description>Bupropion XL (extended release) will be initiated at 150 mg/d on Days 1-4 and increased to 300 mg/d for Days 5-84.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo will be initiated on Day 1 and continue throughout the course of the study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>James C. Garbutt, MD</name_or_title>
      <organization>University of North Carolina at Chapel Hill</organization>
      <phone>919-445-0205</phone>
      <email>jc_garbutt@med.unc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

